Investments
27Portfolio Exits
5Funds
1About Sears Capital Management
Sears Capital Management, Inc. is a venture investment and portfolio management firm specializing in the life sciences. Since its founding in 1994, Sears Capital Management and its affiliated funds have provided seed capital and early stage financing for life science companies and startups.Sears Capital Management's investment areas are pharmaceuticals and medical devices. In addition, Sears Capital Management manages a portfolio of publicly traded life science company stocks.
Sears Capital Management Headquarter Location
300 3rd Street
Los Altos, California, 94022-3628,
United States
Latest Sears Capital Management News
Jan 6, 2017
Amgen will collaborate with SiteOne Therapeutics to develop the Montana-based biotech’s portfolio of novel sodium ion channel 1.7 (NaV1.7) inhibitors for acute and chronic pain, SiteOne said today. While the value of the collaboration was not disclosed, SiteOne did say it formally closed on a $15 million Series B financing round led by Amgen, with participation from founding investors Next Frontier Capital, 2M Companies, Mission Bay Capital, Sears Capital Management, Biobrit, and Z Investments. “This Series B financing and collaboration with Amgen will allow us to accelerate the development of our NaV1.7 therapeutic candidates in multiple potential applications for managing acute and chronic pain without the addiction potential and other significant side-effects of existing therapies,” Stan Abel, SiteOne’s president and CEO, said in a statement. “The opioid crisis in the U.S. has created a critical need for safe and effective nonopioid solutions for managing pain,” Abel added. The company focuses on advancing treatments for moderate to severe pain that target the voltage-gated NaV1.7 channel. According to SiteOne, development of drugs targeting NaV1.7 has been challenging due to the difficulty of achieving selectivity for NaV1.7 over other closely related sodium ion channel isoforms. SiteOne says it has overcome that challenge through its discovery engine, which leverages natural sodium channel inhibitors of marine origin. “NaV1.7 is a target of great interest for neuropathic pain due to its human genetic validation," stated David Reese, svp of translational sciences at Amgen. SiteOne is headquartered in Bozeman, MT, with a research team based at QB3 in San Francisco. The company was founded to commercialize technology licensed from Stanford University and has won more than $3 million in NIH Small Business Innovation Research (SBIR) grant funding in addition to support from its founding investors. To enjoy more articles like this from GEN, click here to subscribe now! ×
Sears Capital Management Investments
27 Investments
Sears Capital Management has made 27 investments. Their latest investment was in SiteOne Inc. as part of their Series B on January 1, 2017.
Sears Capital Management Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
1/6/2017 | Series B | SiteOne Inc. | $15M | No | 1 | |
1/6/2017 | Series B | SiteOne Therapeutics | $15M | No | 12 | |
7/15/2015 | Series A | SiteOne Therapeutics | $1.28M | Yes | 2 | |
7/2/2015 | Series A | |||||
9/23/2014 | Seed |
Date | 1/6/2017 | 1/6/2017 | 7/15/2015 | 7/2/2015 | 9/23/2014 |
---|---|---|---|---|---|
Round | Series B | Series B | Series A | Series A | Seed |
Company | SiteOne Inc. | SiteOne Therapeutics | SiteOne Therapeutics | ||
Amount | $15M | $15M | $1.28M | ||
New? | No | No | Yes | ||
Co-Investors | |||||
Sources | 1 | 12 | 2 |
Sears Capital Management Portfolio Exits
5 Portfolio Exits
Sears Capital Management has 5 portfolio exits. Their latest portfolio exit was Vital Therapies on April 17, 2014.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
4/17/2014 | IPO | Public | 2 | ||
Date | 4/17/2014 | ||||
---|---|---|---|---|---|
Exit | IPO | ||||
Companies | |||||
Valuation | |||||
Acquirer | Public | ||||
Sources | 2 |
Sears Capital Management Fund History
1 Fund History
Sears Capital Management has 1 fund, including Sears Trust.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
---|---|---|---|---|---|
5/31/1994 | Sears Trust | Early-Stage Venture Capital | Closed | $20M | 1 |
Closing Date | 5/31/1994 |
---|---|
Fund | Sears Trust |
Fund Type | Early-Stage Venture Capital |
Status | Closed |
Amount | $20M |
Sources | 1 |
Sears Capital Management Team
1 Team Member
Sears Capital Management has 1 team member, including current Chief Executive Officer, Lowell E. Sears.
Name | Work History | Title | Status |
---|---|---|---|
Lowell E. Sears | Amgen, and J.P. Morgan & Co. | Chief Executive Officer | Current |
Name | Lowell E. Sears |
---|---|
Work History | Amgen, and J.P. Morgan & Co. |
Title | Chief Executive Officer |
Status | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.